Advertisement

RXi Pharmaceuticals Corp. of Worcester and EyeGate Pharmaceuticals Inc. of Waltham today said they will collaborate on an effort to deliver RNAi therapeutics to the eye to treat retinal disorders.

According to RXi president and CEO Noah Beerman, pre-clinical studies of RXi’s sd-rxRNA compounds have shown effective gene silencing in the retina after intraocular injection.

SOURCE

Advertisement
Advertisement